RxDoctor Payments Data

Mahender Gaba, MD

Cardiovascular Disease · Bullhead City, AZNPI 1104896174

Payments from drug & device makers

$13,253in general payments, 2019–2025

Across 217 payments — averaging $61.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abiomed$3K
  • Boston Scientific$961
  • W. L. Gore & Associates, Inc.$904
  • Novartis$624
  • Boehringer Ingelheim$549
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$7,19254%
  • Food & beverage$6,05446%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,253 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$546,543
Medicare patients
1,569
Services billed
5,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$260,271
XareltoRivaroxaban176$218,324
EntrestoSacubitril/Valsartan154$185,345
JardianceEmpagliflozin76$89,992
Repatha SureclickEvolocumab82$69,888
BrilintaTicagrelor32$17,095
Metoprolol Succinate524$8,820
Ezetimibe133$6,608
Atorvastatin Calcium468$4,742
Losartan Potassium305$3,311
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$3,254
Rosuvastatin Calcium114$2,043
Labetalol Hcl45$1,572
Amlodipine Besylate236$1,485
ClopidogrelClopidogrel Bisulfate91$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$260,271243 claims
Johnson & JohnsonXarelto$304$218,324176 claims
NovartisEntresto$624$185,345154 claims
Boehringer IngelheimJardiance$549$89,99276 claims
AstraZenecaBrilinta$52$17,09532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Bullhead City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →